砍中间商、换“白菜价”，特朗普要搞美版药品集采

Core Viewpoint - The U.S. government, under Trump's administration, has initiated an executive order aimed at reducing prescription drug prices by aligning them with those in other developed countries, potentially leading to price reductions of 50% to 90% for certain medications [1][4]. Group 1: U.S. Drug Pricing Landscape - The U.S. accounts for 75% of global pharmaceutical profits despite having only 5% of the world's population, with prescription drug prices averaging 2-4 times higher than in countries like France and Canada [1][2]. - The complex interplay of stakeholders, including pharmaceutical companies, pharmacy benefit managers (PBMs), insurance companies, and pharmacies, contributes to high drug prices, with these groups extracting over 40% of the final drug price [2][3]. Group 2: Implications of the Executive Order - The executive order targets the elimination of middlemen in the drug pricing process, which Trump claims have been entrenched for decades [3][4]. - The actual impact of the order on pharmaceutical companies versus middlemen profits is expected to be a complex negotiation process, as the U.S. insurance market is primarily driven by private insurance [4]. Group 3: Potential Effects on Chinese Pharmaceutical Companies - The order may indirectly benefit Chinese pharmaceutical companies by allowing the import of cheaper drugs from other countries, potentially increasing their market opportunities in the U.S. [6]. - However, the direct impact on Chinese companies remains limited, as only a small number of innovative drugs from China have been approved for sale in the U.S. [7][8]. Group 4: Market Dynamics and Future Considerations - The demand for Chinese pharmaceutical products is expected to remain stable, but the pricing dynamics may shift, leading to potential reductions in transaction values for licensing deals [8][9]. - The long-term effects of the executive order will depend on its implementation and how multinational corporations adjust their pricing strategies in response [9].